  |
The MedWatch August 2012 Safety Labeling Changes posting includes 53 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.
The "Summary Page" provides a listing of drug names and safety labeling sections revised: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm315860.htm The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and/or WARNINGS sections:
Aplenzin (Bupropion Hydrobromide)
Atrovent HFA (Ipratropium Bromide HFA)
Avelox (Moxifloxacin Hydrochloride)
Bactrim (Sulfamethoxazole and Trimethoprim)
Capoten (Captopril)
Coartem (Artemether/Lumefantrine)
Complera (Emtricitabine, Rilpivirine, Tenofovir
Diovan (Valsartan)Bactrim DS (Sulfamethoxazole and Trimethoprim)
Diovan HCT (Valsartan/Hydrochlorothiazide)
Disoproxil Fumarate)
Edurant (Rilpivirine)
Fuzeon (Enfuvirtide)
Intelence (Etravirine)
Invega Sustenna (Paliperidone Palmitrate)
Isentress (Raltegravir)
Lamictal (Lamotrigine) and Lamictal XR (Lamotrigine)
Leustatin (Cladribine)
Lovaza (Omega-3-Acid Ethyl Esters)
Lucentis (Ranibizumab)
Mirapex (Pramipexole Dihydrochloride) and Mirapex ER (Pramipexole Dihydrochloride)
Moviprep (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid)
Neoral Soft Gelatin (Cyclosporine)
Neoral oral Solution (Cyclosporine)
Nexavar (Sorafenib)
Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
Ortho Evra (Norelgestromin/Ethinyl Estradiol)
Oxaliplatin (Oxaliplatin)
Revatio (Sildenafil)
Sanctura XR (Trospium Chloride)
Sandimmune (Cyclosporine, USP)
Selzentry (Maraviroc)
Strattera (Atomoxetine Hydrochloride)
Sustiva (Efavirenz)
Toviaz (Fesoterodine Fumarate)
Tradjenta (Linagliptin)
Trobicin (Spectinomycin)
Ultane and Ultane NovaPlus (Sevoflurane)
Vectibix (Panitumumab)
Viread (Tenofovir Disoproxil Fumarate
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
